Loading clinical trials...
Loading clinical trials...
An Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease
Conditions
Interventions
Anakinra +/- Ruxolitinib (stages 2b/3)
Anakinra and Ruxolitinib (Advanced stage 3)
+3 more
Locations
1
France
Assistance Publique Hôpitaux de Marseille
Marseille, France
Start Date
September 1, 2020
Primary Completion Date
September 30, 2022
Completion Date
November 1, 2022
Last Updated
June 23, 2020
NCT04525716
NCT03188796
NCT06355232
NCT05191420
NCT04611243
NCT04678193
Lead Sponsor
Assistance Publique Hopitaux De Marseille
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions